Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1

Conditions

Multiple Myeloma 61Recurrence 10Lymphoma 5Waldenstrom Macroglobulinemia 4Neoplasms, Plasma Cell 4Small Cell Lung Carcinoma 3Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Kidney Neoplasms 2Hodgkin Disease 2Hematologic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Sezary Syndrome 1Salivary Gland Adenoma, Pleomorphic 1Renal Insufficiency 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1Neoplasm Metastasis 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Plasma Cell 1Leukemia 1Kidney Failure, Chronic 1

Interventions

carfilzomib 1Dexamethasone 1Acyclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Salivary Gland Adenoma, Pleomorphic × carfilzomib × Clear all
NCT02047253 2018-12-19

Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment

University of Alabama at Birmingham

Phase 2 Completed
28 enrolled 12 charts
GenitourinaryHead & Neck

Salivary Gland Adenoma, Pleomorphic, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡